2,500,000 Ordinary Shares and Warrants to Purchase 1,250,000 Ordinary Shares Vascular Biogenics Ltd. EQUITY UNDERWRITING AGREEMENTUnderwriting Agreement • November 5th, 2015 • Vascular Biogenics Ltd. • Pharmaceutical preparations • New York
Vascular Biogenics Ltd., an Israeli company (the “Company”), proposes to sell to the several underwriters (the “Underwriters”) named on Schedule I hereto for whom you are acting as the representative (the “Representative”) (i) an aggregate of 2,500,000 shares (the “Shares”) of the Company’s ordinary shares, NIS 0.01 nominal value (the “Ordinary Shares”) and (ii) warrants of the Company to purchase an aggregate of 1,250,000 Ordinary Shares in the form set forth in Exhibit B (the “Warrants”). The respective amounts of the Shares and Warrants to be so purchased by the several Underwriters are set forth opposite their names on Schedule I hereto. Each Share is being sold together with a Warrant to purchase 0.5 of an Ordinary Share at an exercise price of $7.50 per whole Ordinary Share.
WARRANT AGREEMENTWarrant Agreement • November 5th, 2015 • Vascular Biogenics Ltd. • Pharmaceutical preparations • New York
WARRANT AGREEMENT, dated as of November 4, 2015, between Vascular Biogenics Ltd., a company limited by shares organized under the laws of Israel (the “Company”) and the American Stock Transfer & Trust Company, LLC, acting as warrant agent (the “Warrant Agent”).
